Register for our free email digests:
Latest From Alfa Wassermann SPA
Pharmaceutical revenues were down slightly; so was R&D spending, thanks to a strengthening dollar. Scrip analyzes 620 companies and uses numbers, clocks and tiers to paint some data pictures of the pharmaceutical industry in 2015.
Regulatory authorities in Japan have put back the granting of a reimbursement price to Keytruda under the national health insurance system amid rising worries over the cost of new cancer immunotherapies, delaying the launch of the product for now.
Pipeline Watch has been updated to bring greater depth and detail to a potential therapeutic product’s progress through the R&D pipeline. The table brings you a snapshot of selected late-stage clinical trial events in the pharma and biotech industries.
A large batch of new drugs, indications and formulations just granted approval in Japan includes Keytruda and the first marketing authorization in Asia for Ariad's Iclusig.
- Gene Therapy, Cell Therapy
- Therapeutic Areas
- Activated Cell Therapy
- North America
- Parent & Subsidiaries
- Dendreon Corp.
- Senior Management
W. Thomas Amick, Pres. & CEO
Gregory R Cox, Interim CFO
Andrew S Sandler, MD, EVP, CMO
- Contact Info
Phone: (877) 256-4545
1208 Eastlake Ave. E
Seattle, WA 98102
You must sign in to use this functionality
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.